Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells

Cancer Letters

Volumn 188, Issue 1-2, 2002, Pages 127-140

  Chen, Zunxuan ^a   Clark, Steven ^a   Birkeland, Marian ^a   Sung, Chiu Mei ^a   Lago, Amparo ^a   Liu, Ronggang ^a   Kirkpatrick, Robert ^a   Johanson, Kyung ^a   Winkler, James D ^a   Hu, Erding ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Apoptosis; Butyrate; Growth arrest and DNA damage gene 45 (GADD45); Histone deacetylase (HDAC); p21(cip waf); Trichostatin (TSA)

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BUTYRIC ACID; CURCUMIN; ETICYCLIDINE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P21; SB 242235; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANTIGENS, DIFFERENTIATION; BLOTTING, NORTHERN; BLOTTING, WESTERN; BUTYRATES; CELL CYCLE PROTEINS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYCLOHEXIMIDE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; NUCLEAR PROTEINS; PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 18644367141     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00322-1     Document Type: Article

References (75)

1. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 408:2000;377-381.
2. Boyes J., Byfield P., Nakatani Y., Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 396:1998;594-598.
3. Bayle J.H., Crabtree G.R. Protein acetylation: more than chromatin modification to regulate transcription. Chem. Biol. 4:1997;885-888.
4. Heinzel T., Lavinsky R.M., Mullen T.M., Soderstrom M.L., Laherty C.D., Torchia J., Yang W.M., Brard G., Ngo S.D., Davis J.R., Seto E., Eisenman R.N., Rose D.W., Glass C.K., Rosenfeld M.G. A complex containing N-coR, mSin3 and histone deacetylase mediates transcription repression. Nature. 387:1997;43-48.
5. Laherty C.D., Yang W.M., Sun J.M., Davie J.R., Seto E., Eisenman R.N. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 89:1997;349-356.
6. Kuo M.H., Allis C.D. Role of histone acetylases and deacetylases in gene regulation. Bioessay. 20:1998;615-626.
7. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. J. Cell. Physiol. 184:2000;1-16.
8. Gray S.G., Ekstrom T.J. The human histone deacetylase family. Exp. Cell Res. 262:2001;75-83.
9. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:2000;1210-1216.
10. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 272:1996;408-411.
11. Grozinger C.M., Hassig C.A., Schreiber S.L. Three proteins define a class of human histone deacetylase related to yeast Hda1p. Proc. Natl. Acad. Sci. USA. 96:1999;4868-4873.
12. Yang W.M., Yao Y.L., Sun J.M., Davie J.R., Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 272:1997;28001-28007.
13. Dangond F., Hafler D.A., Tong J.K., Randall J., Kojima R., Utku N., Gullans S.R. Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem. Biophys. Res. Commun. 242:1998;648-652.
14. Buggy J.J., Sideris M.L., Mak P., Lorimer D.D., McIntosh B., Clark J.M. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem. J. 350:2000;199-205.
15. Hu E., Chen Z., Fredrickson T., Zhu Y., Kirkpatrick R., Zhang G.F., Johanson K., Sung C.M., Liu R., Winkler J. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 275:2000;15254-15264.
16. Zhou X., Marks P.A., Rifkind R.A., Richon V.M. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. USA. 98:2001;10572-10577.
17. Tong J.J., Liu J., Bertos N.R., Yang X.J. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res. 30:2002;1114-1123.
18. Fischer D.D., Cai R., Bhatia U., Asselbergs F.A., Song C., Terry R., Trogani N., Widmer R., Atadja P., Cohen D. Isolation and characterization of a novel class II histone deacetylase HDAC10. J. Biol. Chem. 277:2002;6656-6666.
19. Guardiola A.R., Yao T.P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol. Chem. 277:2002;3350-3356.
20. Kao H.Y., Lee C.H., Komarov A., Han C.C., Evans R.M. Isolation and chacterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 277:2002;187-193.
21. McKinsey T.A., Zhang C.L., Lu J., Olson E.N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 408:2000;46-47.
22. Miska E.A., Karlsson C., Langley E., Nielsen S.J., Pines J., Kouzarides T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 18:1999;5099-5107.
23. McKinsey T.A., Zhang C.L., Olson E.N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase5. Proc. Natl. Acad. Sci. USA. 97:2000;14400-14405.
24. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403:2000;795-800.
25. Smith J.S., Brachmann C.B., Celic I., Kenna M.A., Muhammad S., Starai V.J., Avalos J.L., Escalante-Semerena J.C., Grubmeyer C., Wolberger C., Boeke J.D. A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc. Natl. Acad. Sci. USA. 97:2000;6658-6663.
26. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265:1990;17174-17179.
27. Wharton W., Savell J., Cress W.D., Seto E., Pledger W.J. Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A - Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J. Biol. Chem. 275:2000;33981-33987.
28. Yoshida M., Hoshikawa Y., Koseki K., Mori K., Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J. Antibiot. 43:1990;1101-1106.
29. Vigushin D.M., Ali S., Pace P.E., Mirsaidi N., Ito K., Adcock I., Coombes R.C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7:2001;971-976.
30. Yoshida M., Horinouchi S., Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 17:1995;423-430.
31. Kwon H.J., Owa T., Hassig C.A., Shimada J., Schreiber S.L. Depudecin induces morphological reversion of transformed fibroblast via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA. 95:1998;3356-3361.
32. Medina V., Edmonds B., Young G.P., James R., Appleton S., Zalewski P.D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with mitochondiral/cytochrome c-dependent pathway. Cancer Res. 57:1997;3697-3707.
33. Zhou Q., Melkoumian Z.K., Lucktong A., Moniwa M., Davie J.R., Strobl J.S. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J. Biol. Chem. 275:2000;35256-35263.
34. Inokoshi J., Katagiri M., Arima S., Tanaka H., Hayashi M., Kim Y.B., Furumai R., Yoshida M., Horinouchi S., Omura S. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem. Biophys. Res. Commun. 256:1999;372-376.
35. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., Tanimoto M., Murate T., Kawashima K., Saito H., Naoe T. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 13:1999;1316-1324.
36. Siavoshian S., Segain J.P., Kornprobst M., Bonnet C., Cherbut C., Galmiche J.P., Blottiere H.M. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut. 46:2000;507-514.
37. Xiao H.Y., Hasegawa T., Isobe K. Both Sp1 and Sp3 are responsible for p21(waf1) promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem. 73:1999;291-302.
38. Xiao H.Y., Hasegawa T., Miyaishi O., Ohkusu K., Isobe K. Sodium butyrate induces NIH3T3 cells to senescence-like state and enhance promoter activity of p21 (waf/cip) in p53-independent manner. Biochem. Biophys. Res. Commun. 237:1997;457-460.
39. Nakano K., Mizuno T., Sowa Y., Orita T., Yoshino T., Okuyama Y., Fujita T., Ohtanifujita N., Matsukawa Y., Tokino T., Yamagishi H., Oka T., Numura H., Sakai T. Butyrate activates the waf1/cip1 gene promoter through sp1 sites in a p53-negative human colon cancer cells. J. Biol. Chem. 272:1997;22199-22206.
40. Archer S.Y., Meng S.F., Shei A., Hodin R.A. P21(Waf1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA. 95:1998;6791-6796.
41. Han J.W., Ahn S.H., Park S.H., Wang S.Y., Bae G.U., Seo D.W., Kwon H.K., Hong S., Lee H.Y., Lee Y.W., Lee H.W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21(WAF1/Cip1) and gelsolin. Cancer Res. 60:2000;6068-6074.
42. Vaziri C., Stice L., Faller D.V. Butyrate-induced G(1) arrest results from P21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 9:1998;465-474.
43. Kim Y.B., Ki S.W., Yoshida M., Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibiot. 53:2000;1191-1200.
44. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: a Laboratory Manual. 2nd Edition: 1989;Cold Spring Harbor, Cold Spring Harbor, NY.
45. Suzuki T., Yokozaki H., Kuniyasu H., Hayashi K., Naka K., Ono S., Ishikawa T., Tahara E., Yasui W. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int. J. Cancer. 88:2000;992-997.
46. Sen R., Baltimore D. Inducibility of kappa immunogobulin enhancer-binding protein NF-kappa B by posttranslational mechanism. Cell. 47:1986;921-928.
47. Herschman H.R. Primary response genes induced by growth factor and tumor promoters. Annu. Rev. Biochem. 60:1991;281-319.
48. Newton R., Adcock I.M., Barnes P.J. Superinduction of NF-kappa B by actinomycin D and cyclohexamide in epithelial cells. Biochem. Biophys. Res. Commun. 218:1996;518-523.
49. Badger A.M., Griswold D.E., Kapadia R., Blake S., Swift B.A., Hoffman S.J., Stroup G.B., Webb E., Rieman D.J., Gowen M., Boehm J.C., Adams J.L., Lee J.C. Disease-modifying activity of SB242235, a selective inhibitor of p38 mitogen-activated protein kinase in rat adjuvant-induced arthritis. Arthritis Rheum. 43:2000;175-183.
50. Plummer S.M., Holloway K.A., Manson M.M., Munks R.J., Kaptein A., Farrow S., Howells L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 18:1999;6013-6020.
51. Brennan P., O'Neill L.A. Inhibition of nuclear factor kappaB by direct modification in whole cells - Mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem. Pharmacol. 55:1998;965-973.
52. Chen C.C., Chiu K., Y T., Sun T., Chen W.C. Role of the cyclic AMP-protein kinase A pathway in lipopolysaccharide-induced nitric oxide synthase expression in RAW264.7 macrophages. Involvement of cyclooxygenase-2′ J. Biol. Chem. 274:1999;31559-31564.
53. Jee S.H., Shen S.C., Tseng C.R., Chiu H.C., Kuo M.L. Curcumin induces a P53-dependent apoptosis in human basal cell carcinoma cells. J. Invest. Dermatol. 111:1998;656-661.
54. Kosugi H., Ito M., Yamamoto Y., Towatari M., Ito M., Ueda R., Saito H., Naoe T. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn. J. Cancer Res. 92:2001;529-536.
55. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:2000;1210-1216.
56. Hobbs W.E. 2nd, DeLuca N.A. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J. Virol. 73:1999;8245-8255.
57. Sowa Y., Sakai T. Butyrate as a model for 'gene-regulating chemoprevention and chemotherapy'. Biofactors. 12:2000;283-287.
58. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through sp1 sites. Biochem. Biophys. Res. Commun. 241:1997;142-150.
59. Xiao H.Y., Hasegawa T., Isobe K. p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J. Biol. Chem. 275:2000;1371-1376.
60. Fornace A.J.J., Alamo I.J., Hollander M.C. DNA damaging-inducible transcripts in mammlian cells. Proc. Natl. Acad. Sci. USA. 85:1988;8800-8804.
61. Papathanasiou M.A., Kerr N.C.K., Robbins J.H., McBride O.W., Alamo I.J., Barrett S.F., Hickson I.D., Fornace A.J.J. Induction of ionizing radiation of the gadd45 gene in cultured human cells: lack of mediation by protein kinase C. Mol. Cell. Biol. 11:1991;1009-1016.
62. Fornace A.J.J., Nebert D., Hollander M.C., Papathanasiou M.A., Fargnoli J., Holbrook N. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell Biol. 9:1989;4196-4203.
63. Jin S.Q., Zhao H.C., Fan F.Y., Blanck P., Fan W.H., Colchagie A.B., Fornace A.J., Zhan Q.M. BRCA1 activation of the GADD45 promoter. Oncogene. 19:2000;4050-4057.
64. Kastan M.B., Zhan Q., El_Deiry W.S., Carrier F., Jack T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. A. mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
65. Zhan Q.M., Chen I.T., Antinore M.J., Fornace A.J. Tumor suppressor P53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding. Mol. Cell Biol. 18:1998;2768-2778.
66. O'Reilly M.A., Staversky R.J., Watkins R.H., Maniscalco W.M., Keng P.C. P53-independent induction of GADD45 and GADD153 in mouse lungs exposed to hyperoxia. Am. J. Physiol. 278:2000;L552-L559.
67. Ohtanifujita N., Minami S., Mimaki S., Dao S., Sakai T. P53-independent activation of the GADD45 promoter by delta(12)-prostaglandin J(2). Biochem. Biophys. Res. Commun. 251:1998;648-652.
68. Takahashi S., Saito S., Ohtani N., Sakai T. Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation. Cancer Res. 61:2001;1187-1195.
69. Wang X.W., Zhan Q.M., Coursen J.D., Khan M.A., Kontny H.U., Yu L.J., Hollander M.C., PM O.C., Fornace A.J., Harris C.C. GADD45 induction of a G(2)/M cell cycle checkpoint. Proc. Natl. Acad. Sci. USA. 96:1999;3706-3711.
70. Hollander M.C., Sheikh M.S., Bulavin D.V., Lundgren K., Augeri-Henmueller L., Shehee R., Molinaro T.A., Kim K.E., Tolosa E., Ashwell J.D., Rosenberg M.P., Zhan Q.M., Fernandez-Salguero P.M., Morgan W.F., Deng C.X., Fornace A.J. Genomic instability in GADD45α-deficient mice. Nat. Genet. 23:1999;176-184.
71. Kearsey J.M., Coates P.J., Prescott A.R., Warbrick E., Hall P.A. GADD45 is a nuclear cell cycle regulated protein which interacts with P21(Cip1). Oncogene. 11:1995;1675-1683.
72. Smith M.L., Chen I.T., Zhan Q., Bae I., Chen C.Y., Gilmer T.M., Kastan M.B., O'Connor P.M., Fornace A.J.J. Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science. 266:1994;1376-1380.
73. Vairapandi M., Ballier A.G., Fornace A.J.J., Hoffman B., Libermann D.A. The differentiation primary response gene MYD118, related to GADD45 encodes for a nuclear protein which interacts with PCNA and p21 WAF/CIP1. Oncogene. 12:1996;2579-2594.
74. Jin S.Q., Antinore M.J., Lung F.T., Dong X., Zhao H.C., Fan F.Y., Colchagie A.B., Blanck P., Roller P.P., Fornace A.J., Zhan Q.M. The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression. J. Biol. Chem. 275:2000;16602-16608.
75. Carrier F., Zhan Q.M., Alamo I., Hanaoka F., Fornace A.J. Evidence for distinct kinase-mediated pathways in GADD gene responses. Biochem. Pharm. 55:1998;853-861.